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Tacrolimus and diabetic ketoacidosis after kidney transplantation 
in a 15-year-old girl (Case Report) 
 
 
Abstract: 
Tacrolimus is a main drug for induction and maintenance 
immunosuppression for patients with kidney transplants in many centers. 
One of important side effect of drug is post-transplant diabetes mellitus. 
Of course, diabetes ketoacidosis (DKA) is rare. In this report, a 12-year-
old girl with DKA was presented after 45 days of kidney transplantation.  
Keywords: Tacrolimus, Children, diabetes ketoacidosis, Kidney 
Transplantation 
 
 
 
 
 
 
 
 
Introduction: 
Tacrolimus (FK 506) is a calcineurin inhibitor. It was derived from 
streptomyces tsukubaensis .The drug has been used for 
immunosuppression for kidney transplant patients since mid-1990s 
[1-2]
. 
The immunosuppressive effect of tacrolimus (Tac) is same as of 
cyclosporine. It inhibits many T-cell lymphokines productions such as 
interleukin II (IL -2), IL 3, IL4 and gamma interferon. So, the drugs 
suppress T-helper and cytotoxic T-cell function 
[3]
. Due to similar 
mechanism effect of Tac and cyclosporine, the side effects of two drugs 
are the same 
[4]
. One of the major and important side effects of Tac in 
pediatric renal transplantation is post-transplant diabetes mellitus 
(PTDM).This effect of drug may be due to the decrease of insulin 
secretion and may be associated with concurrent use of corticosteroids. 
[5]
. 
Although, the risk of PTDM was higher with Tac than other kidney 
transplant drugs, but the risk of PTDM can be decreased with lower dose 
of Tac 
[6]
. Al-uzri et al reported the incidence of 3% diabetes mellitus 
after kidney transplantation, but the risk of diabetes ketoacidosis (DKA) 
is rare 
[7]
. This case report is a 15 years old girl that was presented with 
PTDM and diabetic ketoacidosis (DKA) after 45 days kidney transplant. 
 
 
Case Report: 
Kidney transplantation (KT) was conducted on a 15-year-old girl on 
26 Feb. 2016. She was on tacrolimus, prednisone and mycofenolate 
mofetile (MMF) for maintenance immunosuppression therapy. About 45 
days of after KT, she was reffered to hospital with headache, polyuria and 
polydipsia. Her laboratory exams on admition time were showed: 
FBS: 482mg/dl, BUN: 34 mg/dl, Creatinin: 1.2 mg/dl, VBG (PH: 7.21, 
HCO2: 5.9, PCO2: 14.7), U/A (WBC: 0-1, RBC: 0-1, SG: 1.025, Sugar: 
1+, Ketone: 1+) 
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She was admitted in hospital with diagnosis of 
diabetes ketoacidosis. She took daily doses of 
prednisolone 25 mg, Tac 8 mg and MMF 500 mg. 
After admission, she was treated by insulin (Crystal 
and NPH) and tacrolimus was changed to cyclosporine. 
Her blood sugar was controlled in hospital during 1 
week and she was discharged with insulin. After 
discharge, her laboratory findings were: 
BUN=23mg/dL, Creatinin=0.9mg/dL, FBS=114mg/dL. 
Her last BUN, Creatinin and FBS were 33, 0.9 and 113 
mg/dl, respectively. 
After discharged, her blood sugar was controlled by 
insulin NPH and its doses were decreased gradually 
and then discontinued after 3 months. 
 
 
Discussion: 
In our case, a girl (15 y/o) was presented with 
PTDM and DK after 45 days of KT. She was taken 
high-dose corticosteroid, MMF and high-dose 
tacrolimus.  
The risk of PTDM after KT on 1580 adult patients 
from 1976 to 2004 was 18.2% and about half of them 
were diagnosed 6 months after transplant 
[8]
. The 
incidences of PTDM in USA were 9.1%, 16% and 12% 
after 3, 12 and 36 months after KT, respectively. Of 
course, 25% of them were presented about 1 year after 
KT 
[9]
. The risk factors for PTDM can be divided into 
non -modifiable and modifiable factors and are 
illustrated in table 1 
[10]
. According to table 1, 
immunosuppressive drugs such as corticosteroid and 
tacrolimus are modifiable risk factors of PTDM.  
The risk of PTDM after KT and corticosteroids 
depends on dose and duration of drug therapy 
[11]
. 
Tacrolimus and cyclosporine are calcineurin inhibitor 
(CNI) drugs .They are main drugs (with others) for 
induction and maintenance immunosuppressive 
therapy. Tacrolimus has higher risk of PTDM and the 
risk of diabetes may be as high as 50% 
[11-13]
. Although 
the risk of PTDM by tacrolimus was not dependent on 
the drug dose, many centers preferred Tac than 
cyclosporine 
[14-16]
. 
The number of glucose transporter type 4 (GLUT-
4) receptors of adipocytes was decreased by Tac and 
then induced hyperglycemia 
[17]
. Also, Tac suppresses 
release from insulin by pancreases 
[18]
. Other reports 
showed Tac can manipulate the response of C-peptide 
and change mitochondrial function of pancreatic B-
cells of pancreas islets. 
[19]
. 
In some studies, the risk of PTDM was reported in 
3% of pediatric renal transplant patients 
[7, 20]
. Serial 
check of blood glucose levels and measurement of Hb 
A1C were recommended every 3 months 
[21]
. A study 
was conducted on 5 children (2 patients had PTDM) 
with history of nephrotic syndrome and they were 
treated by Tac. Two patients had diabetes for 9 months 
and 44 months after the start of Tac, respectively 
[21]
. 
Both patients had relapse of N.S and needed higher 
doses of prednisolone. 
Some risk factors reported for PTMD after KT may 
be due to the obesity, males and African Americans 
[20, 
22]
. In the other study, a12-year-old child was reported 
with history of N.S and treaded by Tac for 5 months. 
She took alternate day prednisolone and enalapril. She 
was referred to hospital with vomiting, abdominal pain, 
hyperglycemia (600mg/dl) and 4 +urine ketone. Her 
blood gas indicated metabolic acidosis and she was 
treated with diagnosis of DKA 
[23]
. She was treated by 
insulin and her insulin therapy was discontinued after 
12 weeks. 
According to our case report, it seems that higher 
dose of corticosteroids for initial treatment of KT and 
Tac is the most important risk factor of PTMD in our 
patients. Although the reports of PTMD with DKA, 
especially, in KT patients were rare, blood glucose 
level of every patient treated by Tac must be monitored 
for early detection of DKA. 
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Table 1. Risk factors for new-onset diabetes after transplantation 
Non-modifiable Modifiable 
Advanced age Obesity 
African American, Hispanic, or South Asian descent Sedentary lifestyle 
Genetic, e.g., HLA B27 Metabolic syndrome 
Adult polycystic kidney disease Viral infections, e.g., HCV, cytomegalovirus 
Previous glucose intolerance, e.g., during pregnancy, 
steroid therapy for renal or non-renal disease 
Corticosteroids 
Male donor Calcineurin-inhibitors (tacrolimus > cyclosporine) 
Deceased donor Sirolimus 
 Acute rejection 
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